Everything below concerns bremelanotide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-11. Numbers and descriptions here follow the published literature rather than marketing material.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-MSH |
| Molecular mass | Approximately 1025 Da | Peptide-scale molecule |
| Route | Subcutaneous injection | Intranasal form used in early research |
| Common synonyms | PT-141; bremelanotide acetate | Research code and salt form |
| Typical storage | 2-8 °C, protected from light | Unopened vial condition |
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
=== Renewed hostilities (September–present) === In early September 2026, the US and Iran resumed trading attacks. Iran continued to use land-based batteries to intercept and obstruct commercial shipping lanes despite a US sanctions campaign, which led to the lowest transit rates through the Strait of Hormuz since the start of the war. After the Yemeni civil war escalated significantly, the conflict spread to a second maritime front. The Strait of Bab al-Mandab crisis began when Iran-backed Houthi forces launched an offensive against the internationally recognized Saudi-backed government along Yemen's western coast. Houthi fighters took control of the Hanish Islands, Perim Island, the coastal town of Dhubab, and the strategically important port city of Mokha during the offensive. The group gained control of the Strait of Bab al-Mandab, a vital global chokepoint, as a result of this advance. On 22 September, indirect "shuttle talks" between Iranian Foreign Minister Abbas Araghchi and US envoys Jared Kushner and Steve Witkoff through international mediators briefly resumed on the sidelines of the United Nations General Assembly in New York City. Iran reiterated its demands for permanent peace through communications sent through a Qatari mediator, including the complete lifting of the naval blockade, the immediate release of frozen Iranian financial assets, the end of the war on all fronts, and the halt to US military actions.
Peña suspended negotiations with Brazil on the revision of Annex C of the Itaipu Treaty, alleging a supposed case of digital espionage by Brazilian authorities between 2022 and 2023. Critical sectors pointed out that the suspension favored Brazil by keeping frozen a key process to correct what they consider a historic disadvantage for Paraguay in the distribution of the benefits of hydroelectricity generated by Itaipu Binacional.
=== N: Diseases of the urogenital system === (N32.1) Vesicointestinal fistula (N36.0) Urethral fistula Innora:between the prostatic utricle and the outside of the body (N64.0) Fistula of nipple (N82) Fistulae involving female genital tract / Obstetric fistula (N82.0) Vesicovaginal fistula: between the bladder and the vagina (N82.1) Other female urinary-genital tract fistulae Cervical fistula: abnormal opening in the cervix (N82.2) Fistula of vagina to small intestine Enterovaginal fistula: between the intestine and the vagina (N82.3) Fistula of vagina to large intestine Rectovaginal: between the rectum and the vagina (N82.4) Other female intestinal-genital tract fistulae (N82.5) Female genital tract-skin fistulae (N82.8) Other female genital tract fistulae (N82.9) Female genital tract fistula, unspecified
Sources: en.wikipedia.org
An MRI artifact is a visual artifact, that is, an anomaly during visual representation. Many different artifacts can occur during magnetic resonance imaging (MRI), some affecting the diagnostic quality, while others may be confused with pathology. Artifacts can be classified as patient-related, signal processing-dependent and hardware (machine)-related.
To have a better chance of detecting Type III artificial sources, Calissendorff suggests taking several photographs in a row, fast enough to fix the movement of turbulence in the atmosphere, applying different photometric filters and looking for dark areas (the case of a Dyson sphere being assembled by a Type II civilization), or analyzing the infrared spectrum of galaxies. A much larger sample of objects should be studied.
These last terms are mostly determined by the interfacial layer as this is the outermost part of the particle, thereby determining the surface interactions. For example, the bridging term only plays a role when the molecules in the interfacial layer tend to polymerize. In the case of nanoparticles made of a crystal, quantum mechanical interactions would be expected, but due to the interfacial layer the cores cannot get close enough to each other, and therefore these interactions are neglectable. An illustrative limit-case are non-charged semiconducting quantum dots (QD) in an ideal fluid. Due to the ideal fluid there is no difference between the QD–QD interaction and the QD–fluid interaction. For only the VDW interaction is of importance in the interaction between the interfacial layers, which are made of the superfluid, and other interfacial layers or the solvent. This means there is no attraction between the particles, so they can be accurately described using the Hard Sphere model.
DROME: Gln-Tyr-Met-Ser-Pro-Cys-His-Phe-Lys-Ile-Cys-Asn-Met-amide APIME: Thr-Met-Ile-Ser-Tyr-Met-Thr-Leu-Cys-His-Phe-Lys-Ile-Cys-Asn-Met-amide DAPPU: Asp-Ser-Tyr-Leu-Ser-Met-Cys-His-Phe-Lys-Leu-Cys-Asn-Leu-amide
Sources: en.wikipedia.org
The predecessor to the CAD, termed an evaporative electrical detector, was first described by Kaufman in 2002 at TSI Inc in US patent 6,568,245 and was based on the coupling of liquid chromatographic approaches to TSI's electrical aerosol measurement (EAM) technology. At around the same time Dixon and Peterson at California State University were investigating the coupling of liquid chromatography to an earlier version of TSI's EAM technology, which they called an aerosol charge detector. Subsequent collaboration between TSI and ESA Biosciences Inc. (now part of Thermo Fisher Scientific), led to the first commercial instrument, the Corona CAD, which received both the Pittsburgh Conference Silver Pittcon Editor's Award (2005) and R&D 100 award (2005). Continued research and engineering improvements in product design resulted in CADs with ever increasing capabilities. The newest iterations of the CAD are the Thermo Scientific Corona Veo Charged Aerosol Detector, Corona Veo RS Charged Aerosol Detector and Thermo Scientific Vanquish Charged Aerosol Detectors.
To annotate the vast amounts of available NGS data, currently a large number of SNPs annotation tools are available. Some of them are specific to specific SNPs while others are more general. Some of the available SNPs annotation tools are as follows SNPeff, Ensembl Variant Effect Predictor (VEP), ANNOVAR, FATHMM, PhD-SNP, PolyPhen-2, SuSPect, F-SNP, AnnTools, SeattleSeq, SNPit, SCAN, Snap, SNPs&GO, LS-SNP, Snat, TREAT, TRAMS, Maviant, MutationTaster, SNPdat, Snpranker, NGS – SNP, SVA, VARIANT, SIFT, LIST-S2, PhD-SNP and FAST-SNP. The functions and approaches used in SNPs annotation tools are listed below. Variant annotation tools use machine learning algorithms to predict variant annotations. Different annotation tools use different algorithms. Common algorithms include: Interval/Random forest-eg.MutPred, SNPeff Neural networks-eg.SNAP Support Vector Machines-e.g. PhD-SNP, SNPs&GO Bayesian classification-eg.PolyPhen-2
== Hazards == As a radioactive material, 226Ra and its decay products can present serious health hazards. Factory workers who worked with radium-containing luminous paint, known as the Radium Girls, often licked the tips of their paintbrushes in order to produce a finer point. In doing so, the workers ingested some of the radioactive paint; this eventually led to serious health problems including cancer, bone damage, and anemia. Several of these workers died from illnesses caused by radium exposure. Many rocks and soils contain low concentrations of 226Ra, which forms from the radioactive decay of naturally occurring uranium. The decay of 226Ra produces radon-222, a radioactive gas that can accumulate in inadequately ventilated homes and other enclosed spaces. Radon exposure is the second leading cause of lung cancer in the United States.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.
Earlier approaches were largely hormonal or psychological in focus, whereas this compound acts on central melanocortin signalling. It is not a vasodilator and does not share the mechanism of phosphodiesterase inhibitors. Head-to-head comparative data are limited.
Placebo responses in desire trials are large, so the average drug-placebo separation is small. Reporting therefore relies on validated questionnaires with statistical ranges. Individual responses vary widely.
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.